Navigation Links
Cancer Drug Appears to Help With Aggressive MS
Date:6/12/2008
Use of cyclophosphamide sees 87% improvement in physical, mental function, study says
THURSDAY, June 12 (HealthDay News) -- High doses of a drug used to fight cancer may reduce disease activity and disability in people with aggressive multiple sclerosis, results of a small trial suggest.
In relapsing-remitting MS, the most common type of the disease, patients experience periods of symptoms followed by stretches of symptom-free remission when they used the immunosuppressant drug cyclophosphamide.
In the two-year open label trial that included nine patients with aggressive relapsing-remitting MS, six men and three women with the average age of 35, received 50 milligrams per kilogram per day of cyclophosphamide intravenously for four consecutive days.
After an average of 23 months follow-up, the patients experienced an average 39.4 percent reduction in disability and an 87 percent improvement on scores of physical and mental function. MRI imaging showed a decrease in the average number of MS-related brain lesions, from 6.5 to 1.2 lesions.
"High-dose cyclophosphamide (sold commercially as Cytoxan or Neosar) induced a functional improvement in most of the patients we studied," wrote lead author Chitra Krishnan of the Bloomberg School of Public Health at Johns Hopkins University in Baltimore, Md. "In many of those patients, the functional improvement was sustained through the length of the study (up to 24 months) despite the absence of any immunomodulatory therapies beyond the initial high-dose cyclophosphamide treatment," she concluded.
The study was published online this week in the journal Archives of Neurology and was expected to be in the August print issue.
Cyclophosphamide has been used in combatting a number of cancers, including lymphomas, multiple myeloma, leukemia, mycosis fungoides, neuroblastoma, ovarian carcinoma, retinoblastoma and breast cancer. The drug affects th
'/>"/>
| Copyright©2008 ScoutNews,LLC. All rights reserved |
Related medicine news :
1. Conventional prognostic factors fail to explain better prostate cancer survival in most Asian men
2. Survival differences by race most apparent in advanced stages of breast cancer
3. MRI finds breast cancer before it becomes dangerous
4. Investigators uncover intriguing clues to why persistent acid reflux sometimes turns into cancer
5. Pathway links inflammation, angiogenesis and breast cancer
6. Radiologists encouraged to look beyond cancer for clinically unseen diseases
7. Diet high in meat, fat and refined grains linked to risk for colon cancer recurrence, death
8. Immune deficiency linked to a type of eye cancer
9. Drop in breast cancer incidence linked to hormone use, not mammograms
10. Breast cancer prevention practices vary across Canada
11. First biomarker discovered that predicts prostate cancer outcome
Post Your Comments:
Related Image:
 |
(Date:6/19/2013)... 19, 2013 Brightree LLC , ... software solutions for the post-acute care industry, has been ranked ... the Healthcare Informatics 100 (HCI 100) list. This ... the U.S. in terms of revenue during the last fiscal ... rate of 85% annually, and the company has built its ...
(Date:6/19/2013)... Boca Raton, FL (PRWEB) June 19, 2013 ... spoke about the positive changes and growth that has occurred ... his nationwide travel club. , Shuman said, "Travel Services has ... program to heights beyond belief. Membership is up, even ... agents to meet the demands of members." , Having been ...
(Date:6/19/2013)... disease Amyotrophic lateral sclerosis (ALS), also known as Lou ... can be classified into four distinct stages, report pathologists ... of Pennsylvania in the Annals of Neurology . ... tissues shows, for the first time, how the fatal ... the central nervous system to other regions of brain ...
(Date:6/19/2013)... derived from a naturally occurring compound (apocynin), has ... with Parkinson,s Disease symptoms by preventing deficits in ... the May 28, 2013 edition of ... postdoctoral fellow at the Medical College of Wisconsin ... Balaraman Kalyanaraman, Ph.D., Harry R. & Angeline ...
(Date:6/19/2013)... Imprivata ®, a leading global provider ... Imprivata OneSign ® leads the single sign-on (SSO) category ... & Services report . CIOs and other healthcare executives ... performance of its products and the quality of its ... is integral to their long-term healthcare IT strategy. ...
Breaking Medicine News(10 mins):Health News:Brightree Debuts on List of Top 100 Healthcare Technology Companies 2Health News:Brightree Debuts on List of Top 100 Healthcare Technology Companies 3Health News:Former Owner Eric Shuman Endorses New Owners and Changes Made in Last Year Since Shuman Sold Travel Services Center at Member Conference 2Health News:Staging system in ALS shows potential tracks of disease progression, Penn study finds 2Health News:Imprivata Tops Single Sign-On Category in KLAS 2013 Mid-Term Performance Review 2Health News:Imprivata Tops Single Sign-On Category in KLAS 2013 Mid-Term Performance Review 3[0] Brightree Debuts on List of Top 100 Healthcare Technology Companies[0] Former Owner Eric Shuman Endorses New Owners and Changes Made in Last Year Since Shuman Sold Travel Services Center at Member Conference[0] Staging system in ALS shows potential tracks of disease progression, Penn study finds[0] Antioxidant shows promise in Parkinson's disease[0] Imprivata Tops Single Sign-On Category in KLAS 2013 Mid-Term Performance Review
... one of the worlds leading causes of blindness could be ... discovery here. , In experiments with laboratory rats, scientists at ... a potential new therapy for uveitis the inflammation of ... the outer surface of the eyeball and includes the iris. ...
... ... Sept. 28 Registered nurses at up to 16,Northern California hospitals, ... strike in October that could involve up to 5,500 RNs at,facilities ... Yuba City and Marysville. Strike notices are being sent today ...
... VAWith extensively drug-resistant tuberculosis, life-threatening drug-resistant respiratory and ... headlines, infectious diseases physicians are applauding Rep. Jim ... introducing H.R. 3697, the Strategies To Address Antimicrobial ... The STAAR Act has the potential to save ...
... 28 Healthcare,Technologies Ltd. (NASDAQ: HCTL ), ... meeting of its shareholders for the approval of,the ... Bioventures,Inc. and Gamida for Life B.V., originally scheduled ... to allow shareholders additional time to fully consider,the ...
... Curtail Infant,Deaths, WASHINGTON, Sept. 28 The ... new civil rights issue" and,requires a revised set ... by the Joint Center for Political and Economic,Studies., ... to Love: Infant Mortality,Commission, which was established by ...
... program is improving air quality, agency claims , , FRIDAY, ... (NOx) from power plants, cars and other industry are ... for less ozone and therefore less smog and healthier ... NOx Budget Trading Program annual report from the U.S. ...
Cached Medicine News:Health News:New discovery may improve treatment of one of the world's leading causes of blindness 2Health News:RNs to Announce October Strike of 5,500 Nurses 2Health News:Infectious diseases experts applaud bill against 'bad bugs' 2Health News:Healthcare Technologies to Reschedule the Shareholders Meeting to Approve the NexGen Biofuels Transaction 2Health News:Healthcare Technologies to Reschedule the Shareholders Meeting to Approve the NexGen Biofuels Transaction 3Health News:Joint Center Says New Approach Required to Reduce Black Infant Mortality 2Health News:Joint Center Says New Approach Required to Reduce Black Infant Mortality 3Health News:Less Smog Now in Eastern U.S.: EPA 2New discovery may improve treatment of one of the world's leading causes of blindnessRNs to Announce October Strike of 5,500 NursesInfectious diseases experts applaud bill against 'bad bugs'Healthcare Technologies to Reschedule the Shareholders Meeting to Approve the NexGen Biofuels TransactionJoint Center Says New Approach Required to Reduce Black Infant MortalityLess Smog Now in Eastern U.S.: EPA
(Date:6/19/2013)... , June 19, 2013 Life Technologies ... a licensing agreement granting Suzhou Ribo Life Sciences ... siRNA therapeutics in China ... formulate proprietary siRNA molecules in combination with Invivofectamine® ... address human diseases with high unmet medical need ...
(Date:6/19/2013)... , 19. Juni 2013 ... mit der Entwicklung von SCS microRESIST™, ... in der Beschichtung mit Parylene gelungen ... von biokompatiblem Parylene mit antimikrobiellen Eigenschaften ... schädlicher Mikroorganismen auf beschichteten medizinischen Geräten. ...
(Date:6/18/2013)... , June 18, 2013 Intercept Pharmaceuticals, Inc. ... company focused on the development and commercialization of novel ... announced the pricing of an underwritten public offering of ... offering price of $33.01 per share. In addition, Intercept ... up to an additional 259,500 shares of common stock. ...
Breaking Medicine Technology:Life Technologies Signs Licensing Agreement with Suzhou Ribo Life Sciences for Development of siRNA Therapeutics in China 2Life Technologies Signs Licensing Agreement with Suzhou Ribo Life Sciences for Development of siRNA Therapeutics in China 3Life Technologies Signs Licensing Agreement with Suzhou Ribo Life Sciences for Development of siRNA Therapeutics in China 4Specialty Coating Systems gibt die Einführung einer neuen antimikrobiellen Parylene-Technologie bekannt 2Intercept Pharmaceuticals Announces Pricing of Public Offering of Common Stock 2[0] Life Technologies Signs Licensing Agreement with Suzhou Ribo Life Sciences for Development of siRNA Therapeutics in China[0] Specialty Coating Systems gibt die Einführung einer neuen antimikrobiellen Parylene-Technologie bekannt[0] Intercept Pharmaceuticals Announces Pricing of Public Offering of Common Stock
... Today, the U.S. Food and Drug Administration (FDA) released final label ... long-acting beta-agonist (LABA). This follows the FDA communication on 18 February ... , , , ... ) , , , ...
... June 2 At a time when employers are seeking innovative ... revealed that the integration of medical and pharmacy benefits lowers overall medical ... , , ... employers choose a "carve-out" model by contracting with a pharmacy benefits manager ...
Cached Medicine Technology:FDA Updates U.S. Product Labels for LABA-Containing Medications Including AstraZeneca's SYMBICORT 2FDA Updates U.S. Product Labels for LABA-Containing Medications Including AstraZeneca's SYMBICORT 3FDA Updates U.S. Product Labels for LABA-Containing Medications Including AstraZeneca's SYMBICORT 4FDA Updates U.S. Product Labels for LABA-Containing Medications Including AstraZeneca's SYMBICORT 5FDA Updates U.S. Product Labels for LABA-Containing Medications Including AstraZeneca's SYMBICORT 6Highmark Study Shows Integrated Medical and Pharmacy Benefits Lower Costs, Promote Better Health 2Highmark Study Shows Integrated Medical and Pharmacy Benefits Lower Costs, Promote Better Health 3Liquichek Autoimmune Controls are individual controls for monitoring the performance of autoimmune assays....
... BD Beaver Clear Cornea Incision System ... specifically for the Cataract surgeon. The System ... an alternative to costly diamond knives. ... shield that is designed to both protects ...
... Carl Zeiss Meditec's technological expertise ... retinal disease became apparent with revolutionary ... system. Now, with the introduction of ... expertise is being applied to high-resolution, ...
... the eyeglasses in the EZ Meter and ... automatically display the measurement results on its ... detection to data printout makes this the ... and private offices.,In addition to being extremely ...
Medicine Products:| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |